SALICYLIDENE SALICYLHYDRAZIDE manufacturers
- SCS
-
- $36.00 / 10mg
-
2024-11-19
- CAS:3232-36-8
- Min. Order:
- Purity: 98.89%
- Supply Ability: 10g
|
| SALICYLIDENE SALICYLHYDRAZIDE Basic information |
| SALICYLIDENE SALICYLHYDRAZIDE Chemical Properties |
Hazard Codes | Xn | Risk Statements | 22-36/37/38 | Safety Statements | 26-36-37 | WGK Germany | 3 | TSCA | Yes | HS Code | 29280000 |
| SALICYLIDENE SALICYLHYDRAZIDE Usage And Synthesis |
Uses | SCS is a selective inhibitor of β1-containing GABAA receptors. | Definition | ChEBI: 2-hydroxy-N'-[(6-oxo-1-cyclohexa-2,4-dienylidene)methyl]benzohydrazide is a member of salicylamides. | Biological Activity | Potent and selective partial inhibitor of β 1-containing GABA A receptors (IC 50 values are 4.5, 5.3 and 7.9 nM at α 2 β 1 γ 1 θ , α 2 β 1 γ 1 and α 2 β 1 γ 2s GABA A receptors respectively). May bind allosterically to a novel site on GABA A receptor. | in vivo | SCS (Salicylidene salicylhydrazide; 500-1000 mg/kg, i.p. or 800-1000 mg/kg, oral) produces abdominal constrictions in mice[2].
SCS (10-75 mg/kg; i.p.; once) shows antinociceptive activity against tonic, phasic and Capsaicin (HY-10448) nociception in mice[2].
SCS (10-75 mg/kg; i.p.; once) shows anti-inflammatory activity in mice[2].
SCS (50 and 75 mg/kg; i.p.; once) shows antinociceptive activity against neuropathic nociception[2].
Animal Model: | BALB/c mice; tonic, phasic and Capsaicin (HY-10448) nociception model[2] | Dosage: | 10, 25, 50, and 75 mg/kg | Administration: | IP, single dose | Result: | Produced a significant protection on tonic, phasic and capsaicin nociception in a dose-dependent manner. |
Animal Model: | BALB/c mice, Oxaliplatin (HY-17371)-induced neuropathic nociception model[2] | Dosage: | 50 and 75 mg/kg | Administration: | IP, single dose | Result: | Significantly attenuated the paw withdrawal threshold changes associated with Oxaliplatin. Significantly increased the percent antinociception during 30-120 min.
|
|
| SALICYLIDENE SALICYLHYDRAZIDE Preparation Products And Raw materials |
|